



***SYNTHESIS OF TRANSITION METAL COMPLEXES CONTAINING
SYMMETRICAL CHALCONE-DERIVED SCHIFF BASES AND
CYTOTOXIC STUDIES AGAINST BLADDER CANCER CELLS***

NABEEL ARIF TAWFEEQ

FS 2019 60



**SYNTHESIS OF TRANSITION METAL COMPLEXES CONTAINING
SYMMETRICAL CHALCONE-DERIVED SCHIFF BASES AND
CYTOTOXIC STUDIES AGAINST BLADDER CANCER CELLS**

By

NABEEL ARIF TAWFEEQ

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

May 2019

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

**SYNTHESIS OF TRANSITION METAL COMPLEXES CONTAINING
SYMMETRICAL CHALCONE-DERIVED SCHIFF BASES AND
CYTOTOXIC STUDIES AGAINST BLADDER CANCER CELLS**

By

NABEEL ARIF TAWFEEQ

May 2019

Chairman : Mohamed Ibrahim Mohamed Tahir, D.Phil.
Faculty : Science

Dithiocarbazate Schiff bases and their derivatives have drawn considerable attention due to their unique properties and applications. Many dithiocarbazate metal complexes have been synthesised and applied in many applications such as antibacterial, antifungal, antioxidant agents and in catalysis. Dithiocarbazate metal complexes have also shown significant cytotoxicity against many types of cancer cell lines. This study aims to synthesise non-toxic compounds by synthesising para substituted chalcone derivatives and studying the effect of substituted functional group electronegativity on the cytotoxicity of the metal complexes. Nine chalcones were synthesised using base-catalysed Aldol condensation. The chalcones were symmetrical in order to direct the electron density towards the transition metal in the complexes. These symmetrical chalcones were then reacted with S-benzylthiocarbazate to form nine novel Schiff bases. A total of 45 novel metal complexes were synthesised by reacting these nine Schiff bases with five divalent transition metal acetates which were Ni^{2+} , Fe^{2+} , Cu^{2+} , Zn^{2+} and Cd^{2+} . These Schiff bases and their metal complexes were fully characterised using various characterisation techniques including FTIR, UV-Vis, ^1H and ^{13}C NMR spectroscopy, mass spectral, elemental analysis, and single crystal X-ray diffraction. The cytotoxic properties of these compounds were also tested against two types of bladder cancer cell lines which were the minimum-invasive human bladder cancer carcinoma cell line (RT112) and the invasive human bladder carcinoma cell line (EJ28). All Schiff bases were inactive against both types of bladder cancer cell. The unsubstituted chalcones and their metal complexes were inactive against both cells which means the substituted group on benzene ring plays an important role toward the cytotoxicity of metal complexes. Cu(II) complexes of DTASB, DEASB, DIPASB, DCLASB, DBRASB, DNNMASB and DMeOSB showed moderate cytotoxicity against both cell lines with more selectivity toward EJ-28 than RT-112. Less than that, Zn(II) complexes of DTASB, DEASB and DIPASB showed moderate activity against bladder cancer cell line type EJ-28 while they were inactive against RT-112 cell lines.

An Fe(II) complex, FeDMeOSB, showed moderate activity against both cell lines. CuDMeOSB showed highest cytotoxicity against both types of bladder cancer cell lines EJ-28 and RT-112 with IC_{50} values equal to 1.651 and 1.762 μM , respectively. In addition, CuDNNMASB showed more selectivity against RT-112 than EJ-28 with IC_{50} value equal to 1.874 μM .



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

SINTESIS KOMPLEKS LOGAM PERALIHAN MENGANDUNGI BES SCHIFF TERBITAN KALKON BERSIMETRI DAN KAJIAN SITOTOKSIK TERHADAP SEL KANSER PUNDI

Oleh

NABEEL ARIF TAWFEEQ

Mei 2019

Pengerusi : Mohamed Ibrahim Mohamed Tahir, D.Phil.
Fakulti : Sains

Bes Schiff ditiokarbazot dan terbitannya telah mendapat perhatian yang besar disebabkan oleh sifat dan aplikasi unik mereka. Banyak kompleks logam ditiokarbazot telah disintesis dan digunakan dalam banyak aplikasi seperti antibakteria, antikulat, agen antioksidan dan pemangkinan. Kompleks logam ditiokarbazot juga menunjukkan sitotoksiti yang ketara terhadap pelbagai jenis sel kanser. Kajian ini bertujuan untuk mensintesis sebatian bukan toksik dengan mensintesis terbitan para kalkon gantian dan mengkaji kesan keelektronegatifan kumpulan fungsi yang digantikan pada kesitotoksikan kompleks logam. Sembilan kalkon telah disintesis dengan menggunakan pemeluwapan Aldol berbes. Kalkon ini kemudiannya bertindak balas dengan S-benzilditiokarbazot untuk membentuk sembilan novel bes Schiff. Empat puluh lima kompleks logam novel telah disintesis dengan bertindak balas terhadap sembilan bes Schiff dengan lima asetat logam peralihan divalen iaitu Ni^{2+} , Fe^{2+} , Cu^{2+} , Zn^{2+} dan Cd^{2+} . Bes Schiff dan kompleks logam mereka telah dicirikan sepenuhnya menggunakan teknik pencirian pelbagai termasuk spektroskopi FTIR, UV-Vis, ^1H & ^{13}C NMR, spektrum jisim, analisis unsur, dan pembelauan sinar-X hablur tunggal. Sifat sitotoksik sebatian ini juga diuji terhadap dua jenis sel kanser pundi iaitu sel karsinoma kanser pundi manusia yang kurang invasif (RT112) dan sel karsinoma kanser pundi manusia yang invasif (EJ28). Semua bes Schiff tidak aktif terhadap kedua-dua jenis sel kanser pundi. Kalkon yang tiada gantian dan kompleks logam mereka tidak aktif terhadap kedua-dua sel bermaksud kumpulan yang digantikan pada gelang benzena memainkan peranan penting ke arah kesitotoksikan kompleks logam. Kompleks Cu(II) dengan DTASB, DEASB, DIPASB, DCLASB, DBRASB, DNNMASB dan DMeOSB menunjukkan kesitotoksikan sederhana terhadap kedua-dua sel sel dengan lebih selektif ke arah EJ-28 daripada RT-112. Kompleks Zn(II) dengan DTASB, DEASB dan DIPASB menunjukkan aktiviti sederhana terhadap jenis sel kanser pundi jenis EJ-28 sementara mereka tidak aktif terhadap sel RT-112. Kompleks Fe(II), FeDMeOSB, menunjukkan aktiviti sederhana terhadap kedua-dua

sel. CuDMeOSB menunjukkan kesitotoksikan tertinggi terhadap kedua-dua jenis sel kanser pundi EJ-28 dan RT-112 dengan nilai IC_{50} bersamaan dengan 1.651 dan 1.762 μM masing-masing. Di samping itu, CuDNNMASB menunjukkan lebih banyak kepilihan terhadap RT-112 daripada EJ-28 dengan nilai IC_{50} bersamaan dengan 1.874 μM .



ACKNOWLEDGEMENTS

First and foremost, I would like to acknowledge and thank my project supervisor, Dr Mohamed Ibrahim Mohamed Tahir, for his supporting, patience, wisdom, encouragements and invaluable guidance during my PhD study. I will forever remember those long talks we had in both academic and personal matters. I would also like to thank Assoc. Prof. Dr Thahira Begum, who has also been there for her advice, encouragement, friendship and guidance. I am also grateful to Assoc. Prof. Dr Abhimanyu for his advice, guidance and using his lab for doing cytotoxicity part in this project. Also I would like to thank Dr Mohd Farid for his guidance and advice.

Special thanks to Prof. Karen A. Crouse for her advice, supporting and motivation. I am also indebted to all lecturers, the laboratory technicians and staff in the Faculty of Science and Faculty of Medicine for helping me throughout my PhD study.

I would like to thank my dear labmates: Nadia Enis, Fatiha, Fadila, Chah Chee Keong, Lee Chin, Ali, Idris, Nabihah and Nazirah. We have had a lot of sweet memories together.

Last but not least, I gratefully thank my wife Iqbal and my sons Farooq, Husham, Ahmed and my daughter Haneen for their encouragements, supporting and unconditional love. Special thanks to my father, mother. Also I would like to thank my brothers Kamal, Waleed, Tagreed and Waiel.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirements for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Mohamed Tahir Mohamed Ibrahim, D. Phil.

Senior Lecturer
Faculty of Science
Universiti Putra Malaysia
(Chairman)

Thahira Begum, PhD

Associate Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

Mohd Farid Ismail, PhD

Senior Lecturer
Faculty of Science
Universiti Putra Malaysia
(Member)

Abhimanyu Veerakumarasivam, PhD

Professor
Department of Biological Sciences, School of Science and Technology
Sunway University
(Member)

ROBIAH BINTI YUNIS, PhD

Professor and Dean
School and Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice Chancellor (research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: _____

Name and Matric No.: Nabeel Arif Tawfeeq, GS42850

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of Chairman
of Supervisory

Committee:

Dr. Mohamed Tahir Mohamed Ibrahim

Signature: _____

Name of Member
of Supervisory

Committee:

Associate Professor Dr. Thahira Begum

Signature: _____

Name of Member
of Supervisory

Committee:

Dr. Mohd Farid Ismail

Signature: _____

Name of Member
of Supervisory

Committee:

Professor Dr. Abhimanyu Veerakumarasivam

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xii
LIST OF FIGURES	xiv
LIST OF APPENDICES	xviii
LIST OF ABBREVIATIONS	xxix
CHAPTER	
1 INTRODUCTION	1
1.1 General	1
1.2 Dibenzalacetone Ketones	3
1.3 Dithiocarbazate	6
1.4 Schiff bases	7
1.5 Metal complexes	8
1.6 Cytotoxicity	10
1.7 Problem statements	10
1.8 Objectives	11
2 LITERATURE REVIEW	12
2.1 Chalcones	12
2.2 Dithiocarbazate	13
2.3 S-substituted dithiocarbazate Schiff bases	15
2.4 Biological activity of dithiocarbazate Schiff bases and their metal complexes	18
2.5 Chalcone dithiocarbazate Schiff bases	19
2.6 The advantages of using metal complexes as anticancer drug	24
2.7 Selection of transition metals	28
2.7.1 Nickel	28
2.7.2 Copper	29
2.7.3 Cadmium	29
2.7.4 Zinc	29
2.7.5 Iron	30
3 MATERIALS AND METHODS	31
3.1 Chemicals	31
3.2 Preparation of S-benzylthiocarbazate (SBDTC)	31
3.3 Preparation of Ketones	32
3.3.1 Preparation of Dicinnamalacetone (1 <i>E</i> ,3 <i>E</i> ,6 <i>E</i> ,8 <i>E</i>)-1,9-diphenylnona-1,3,6,8-tetraen-5-one	32
3.3.2 Preparation of Dibenzalacetone (1 <i>E</i> ,4 <i>E</i>)-1,5-diphenylpenta-1,4-dien-3-one	32

3.4	Preparation of Schiff Bases	33
3.5	Preparation of Metal Complexes	34
3.6	Physico-chemical Measurements, Elemental and Spectral Analysis	35
3.6.1	Melting Point Measurements	35
3.6.2	CHNS Analysis	35
3.6.3	Transition Metal Analysis	36
3.6.4	Conductivity Measurements	36
3.6.5	Magnetic Susceptibility Measurements	36
3.6.6	Fourier Transformer Infrared (FTIR) Spectrophotometric Analysis	36
3.6.7	Ultraviolet-Visible Spectrophotometric Analysis	36
3.6.8	Nuclear Magnetic Resonance Analysis (^1H & ^{13}C -NMR)	37
3.6.9	Mass Spectroscopic Analysis	37
3.7	Structure Determination	37
3.8	Cytotoxic Assay	37
4	RESULTS AND DISCUSSION	39
4.1	Physical Properties	39
4.2	Elemental Analysis	41
4.3	FT-IR Spectroscopy Analysis (Fourier Transform Infrared)	43
4.4	Nuclear Magnetic Resonance Spectroscopic Analysis (NMR)	47
4.5	Mass Spectra Analysis (MS-Spectroscopy)	53
4.6	Molar Conductivity and Magnetic Moment	58
4.7	Ultraviolet-visible spectrophotometric analysis	61
4.8	Crystal Structure analysis	66
4.8.1	Ketones	66
4.8.2	Schiff Base Ligands	69
4.8.3	Transition Metal Complexes	70
4.8.3.1	NiDCLASB Metal Complex	70
4.8.3.2	NiDTASB Metal Complex	71
4.8.3.3	NiDEASB Metal Complex	74
4.8.3.4	CdDEASB Metal Complex	75
4.8.3.5	ZnDBRASB Metal Complex	77
4.8.3.6	ZnDCLASB Metal Complex	79
4.8.3.7	ZnDEASB Metal Complex	80
4.8.3.8	ZnDIPASB Metal Complex	82
4.9	Cytotoxic Assay	84
5	CONCLUSION	89
5.1	Summary	89
5.2	Conclusion	90
5.3	Limitations and Recommendations	91
	REFERENCES	92
	APPENDICES	105
	BIODATA OF STUDENT	209
	LIST OF PUBLICATIONS	210

LIST OF TABLES

Table	Page	
1.1	Dibenzalacetone derivatives used in this study	4
1.2	The synthesised transition metal complexes	9
2.1	The publication of dithiocarbazate derivatives	15
3.1	Yields and melting points of synthesised ketones	33
3.2	Physical properties, yields and melting points of synthesised Schiff bases	34
3.3	Colours, yields and melting points of synthesised metal complexes	34
4.1	Physical properties of the synthesized compounds	40
4.2	The elemental analysis data of SBDTC, ketones, Schiff bases and their transition metal complexes	41
4.3	Selected infrared bands of SBDTC, chalcones, and their Schiff bases	44
4.4	Selected infrared bands of Schiff bases and their metal complexes	46
4.5	¹ H NMR data of the synthesised ketones	49
4.6	¹³ C NMR data of the synthesised ketones	50
4.7	¹ H NMR data of the synthesised Schiff bases	50
4.8	¹³ C NMR data of the synthesised Schiff bases	50
4.9	The theoretical and experimental values of the synthesised Schiff bases base peaks	58
4.10	Molar conductance and magnetic moment of the metal complexes	59
4.11	UV-Vis data for SBDTC, ketones, Schiff bases and their transition metal complexes	63
4.12	Selected Bond Angles (°) and Bond Lengths (Å) for DTA	67
4.13	Selected Bond Angles (°) and Bond Lengths (Å) for DBRA	68
4.14	Selected Bond Angles (°) and Bond Lengths (Å) for DMeO	68
4.15	Selected Bond Angles (°) and Bond Lengths (Å) for DMeOSB	69

4.16	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for NiDCLASB	70
4.17	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for NiDTASB	73
4.18	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for NiDEASB	75
4.19	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for CdDEASB	76
4.20	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for ZnDBRASB	78
4.21	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for ZnDCLASB	79
4.22	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for ZnDEASB	81
4.23	Selected Bond Angles ($^{\circ}$) and Bond Lengths (\AA) for ZnDIPASB	83
4.24	Cytotoxic activity of the active compounds against both types of bladder cancer cell lines EJ-28 and RT-112	87

LIST OF FIGURES

Figure	Page	
1.1	General chemical structure of dibenzalacetone	3
1.2	Base catalyzed Aldol condensation mechanism	5
1.3	Chemical structure of dicinnamalacetone DCNMA	5
1.4	Molecular structure of (a) semicarbazide, (b) carbazate, (c) thiosemicarbazide and (d) dithiocarbazate	6
1.5	Chemical structure of Schiff base	7
1.6	Thione-Thiol tautomerism	7
1.7	Reaction scheme of Schiff bases synthesis and chemical structure of the synthesized Schiff bases	8
1.8	General chemical structure of the transition metal complexes	9
2.1	ORTEP diagram of di- <i>p</i> -fluorobenzalacetone with 50% probability displacement ellipsoids	12
2.2	ORTEP diagram of di- <i>p</i> -tolualacetone with 50% probability displacement ellipsoids	12
2.3	Various derivatives of dithiocarbazate	14
2.4	Different aromatic carbonyl compounds used to prepare dithiocarbazate Schiff bases	16
2.5	Different heterocyclic carbonyl compounds used to prepare dithiocarbazate Schiff bases	16
2.6	Different ferrocene derivatives used to prepare dithiocarbazate Schiff bases	17
2.7	Different phosphorous compounds used to prepare dithiocarbazate Schiff bases	17
2.8	Different chiral compounds used to prepare dithiocarbazate Schiff bases	18
2.9	Organophosphorus Chalcones Schiff bases with SBDT and thiosemicarbazide	21

2.10	Ferrocene-based chalcones synthesis route	22
2.11	Ferrocene-based chalcones SBDTC Schiff bases synthesis route	22
2.12	Structure Ferrocene-chalcone SBDTC metal complexes	23
2.13	Chemical structure of chalcone and phenylbutanone	23
2.14	ORTEP diagram of Zn(II) complex derived from S-4-methylbenzylidithiocarbazate and furaldehyde with 50% probability displacement ellipsoids	24
2.15	ORTEP diagram of Cd(II) complex derived from S-4-methylbenzylidithiocarbazate and furaldehyde with 50% probability displacement ellipsoids	25
2.16	ORTEP diagram of Cu(II) complex derived from S-hexyldithiocarbazate and 4-methoxybenzaldehyde with 50% probability displacement ellipsoids	26
2.17	ORTEP diagram of Ni(II) complex derived from S-cyclohexyldithiocarbazate and 4-methoxybenzaldehyde with 50% probability displacement ellipsoids (Begum <i>et al.</i> , 2017)	27
2.18	ORTEP diagram of Cu(II) complex derived from S-benzylidithiocarbazate and 2,4,5-trimethoxybenzaldehyde with 50% probability displacement ellipsoids (Islam <i>et al.</i> , 2016)	28
3.1	Reaction scheme for synthesis of chalcones, Schiff bases and their metal complexes	33
4.1	FT-IR spectra of SBDTC, DBA and DBASB	43
4.2	FT-IR spectra of DBASB Schiff Base and its Fe(II) metal complex	45
4.3	¹ H NMR spectrum of DBA in deuterated methanol	47
4.4	¹ H NMR spectrum of DBASB in deuterated methanol	48
4.5	¹³ C NMR spectrum of DBA in deuterated methanol	48
4.6	¹³ C NMR spectrum of DBASB in deuterated methanol	49
4.7	¹ H NMR spectrum of SBDTC in deuterated chloroform	52
4.8	¹³ C NMR spectrum of SBDTC in deuterated chloroform	53
4.9	The Main Mass Fragments for DBASB	54

4.10	The Main Mass Fragments for DCNMASB	54
4.11	The Main Mass Fragments for DTASB	55
4.12	The Main Mass Fragments for DEASB	55
4.13	The Main Mass Fragments for DIPASB	56
4.14	The Main Mass Fragments for DCLASB	56
4.15	The Main Mass Fragments for DBRASB	57
4.16	The Main Mass Fragments for DMeOSB	57
4.17	The Main Mass Fragments for DNNMASB	58
4.18	UV-Vis spectrum for SBDTC dissolved in acetonitrile	61
4.19	UV-Vis spectrum for DBA dissolved in acetonitrile	62
4.20	UV-Vis spectrum for DBASB dissolved in acetonitrile	62
4.21	UV-Vis spectrum for NiDBASB dissolved in acetonitrile	63
4.22	ORTEP Diagram of DTA where the hydrogen atoms are hidden	67
4.23	ORTEP Diagram of DBRA where the hydrogen atoms are hidden	67
4.24	ORTEP Diagram of DMeO where the hydrogen atoms are hidden	68
4.25	ORTEP Diagram of DMeOSB where the hydrogen atoms are hidden	69
4.26	ORTEP Diagram of NiDCLASB where the hydrogen atoms are hidden	71
4.27	ORTEP Diagram of NiDTASB where the hydrogen atoms are hidden	72
4.28	ORTEP Diagram of NiDEASB where the hydrogen atoms are hidden	74
4.29	ORTEP Diagram of CdDEASB where the hydrogen atoms are hidden	76
4.30	ORTEP Diagram of ZnDBRASB where the hydrogen atoms are hidden	77
4.31	ORTEP Diagram of ZnDCLASB where the hydrogen atoms are hidden	79
4.32	ORTEP Diagram of ZnDEASB where the hydrogen atoms are hidden	81

4.33	ORTEP Diagram of ZnDIPASB where the hydrogen atoms are hidden	83
4.34	Pre-screening bar chart for DBASB and its metal complexes against bladder cancer cell line type RT-112	85
4.35	Pre-screening bar chart for DNNMASB and its metal complexes against bladder cancer cell line type RT-112	86
4.36	The percentage of living cells after treatment with different concentrations of CuDNNMASB complex to determine the IC ₅₀ value	86



LIST OF APPENDICES

Appendix		Page
A 1	IR spectrum of SBDTC	105
A 2	IR spectrum of DBA	105
A 3	IR spectrum of DBASB	106
A 4	IR spectrum of NiDBASB	106
A 5	IR spectrum of CuDBASB	107
A 6	IR spectrum of FeDBASB	107
A 7	IR spectrum of CdDBASB	108
A 8	IR spectrum of ZnDBASB	108
A 9	IR spectrum of DCNMA	109
A 10	IR spectrum of DCNMASB	109
A 11	IR spectrum of NiDCNMA	110
A 12	IR spectrum of CuDCNMA	110
A 13	IR spectrum of FeDCNMA	111
A 14	IR spectrum of CdDCNMA	111
A 15	IR spectrum of ZnDCNMASB	112
A 16	IR spectrum of DTA	112
A 17	IR spectrum of DTASB	113
A 18	IR spectrum of NiDTASB	113
A 19	IR spectrum of CuDTASB	114
A 20	IR spectrum of FeDTASB	114
A 21	IR spectrum of CdDTASB	115
A 22	IR spectrum of ZnDTASB	115

A 23	IR spectrum of DEA	116
A 24	IR spectrum of DEASB	116
A 25	IR spectrum of NiDEASB	117
A 26	IR spectrum of CuDEASB	117
A 27	IR spectrum of FeDEASB	118
A 28	IR spectrum of CdDEASB	118
A 29	IR spectrum of ZnDEASB	119
A 30	IR spectrum of DIPA	119
A 31	IR spectrum of DIPASB	120
A 32	IR spectrum of NiDIPASB	120
A 33	IR spectrum of CuDIPASB	121
A 34	IR spectrum of FeDIPASB	121
A 35	IR spectrum of CdDIPASB	122
A 36	IR spectrum of ZnDIPASB	122
A 37	IR spectrum of DCLA	123
A 38	IR spectrum of DCLASB	123
A 39	IR spectrum of NiDCLASB	124
A 40	IR spectrum of CuDCLASB	124
A 41	IR spectrum of FeDCLASB	125
A 42	IR spectrum of CdDCLASB	125
A 43	IR spectrum of ZnDCLASB	126
A 44	IR spectrum of DBRA	126
A 45	IR spectrum of DBRASB	127
A 46	IR spectrum of NiDBRASB	127
A 47	IR spectrum of CuDBRASB	128

A 48	IR spectrum of FeDBRASB	128
A 49	IR spectrum of CdDBRASB	129
A 50	IR spectrum of ZnDBRASB	129
A 51	IR spectrum of DMeO	130
A 52	IR spectrum of DMeOSB	130
A 53	IR spectrum of NiDMeOSB	131
A 54	IR spectrum of CuDMeOSB	131
A 55	IR spectrum of FeDMeOSB	132
A 56	IR spectrum of CdDMeOSB	132
A 57	IR spectrum of ZnDMeOSB	133
A 58	IR spectrum of DNNMA	133
A 59	IR spectrum of DNNMASB	134
A 60	IR spectrum of NiDNNMASB	134
A 61	IR spectrum of CuDNNMASB	135
A 62	IR spectrum of FeDNNMASB	135
A 63	IR spectrum of CdDNNMASB	136
A 64	IR spectrum of ZnDNNMASB	136
B 1	¹ H NMR Spectrum of SBDTC	137
B 2	¹³ C NMR Spectrum of SBDTC	137
B 3	¹ H NMR Spectrum of DBA	138
B 4	¹³ C NMR Spectrum of DBA	138
B 5	¹ H NMR Spectrum of DBASB	139
B 6	¹³ C NMR Spectrum of DBASB	139
B 7	¹ H NMR Spectrum of DCNMA	140
B 8	¹³ C NMR Spectrum of DCNMA	140

B 9	^1H NMR Spectrum of DCNMASB	141
B 10	^{13}C NMR Spectrum of DCNMASB	141
B 11	^1H NMR Spectrum of DTA	142
B 12	^{13}C NMR Spectrum of DTA	142
B 13	^1H NMR Spectrum of DTASB	143
B 14	^{13}C NMR Spectrum of DTASB	143
B 15	^1H NMR Spectrum of DEA	144
B 16	^{13}C NMR Spectrum of DEA	144
B 17	^1H NMR Spectrum of DEASB	145
B 18	^{13}C NMR Spectrum of DEASB	145
B 19	^1H NMR Spectrum of DIPA	146
B 20	^{13}C NMR Spectrum of DIPA	146
B 21	^1H NMR Spectrum of DIPASB	147
B 22	^{13}C NMR Spectrum of DIPASB	147
B 23	^1H NMR Spectrum of DCLA	148
B 24	^{13}C NMR Spectrum of DCLA	148
B 25	^1H NMR Spectrum of DCLASB	149
B 26	^{13}C NMR Spectrum of DCLASB	149
B 27	^1H NMR Spectrum of DBRA	150
B 28	^{13}C NMR Spectrum of DBRA	150
B 29	^1H NMR Spectrum of DBRASB	151
B 30	^{13}C NMR Spectrum of DBRASB	151
B 31	^1H NMR Spectrum of DMeO	152
B 32	^{13}C NMR Spectrum of DMeO	152
B 33	^1H NMR Spectrum of DMeOSB	153

B 34	^{13}C NMR Spectrum of DMeOSB	153
B 35	^1H NMR Spectrum of DNNMA	154
B 36	^{13}C NMR Spectrum of DNNMA	154
B 37	^1H NMR Spectrum of DNNMASB	155
B 38	^{13}C NMR Spectrum of DNNMASB	155
C 1	Mas Spectrum of SBDTC	156
C 2	Mas Spectrum of DBASB	156
C 3	Mass Fragmentation of DBASB	157
C 4	Mas Spectrum of DCNMASB	157
C 5	Mass Fragmentation of DCNMASB	158
C 6	Mas Spectrum of DTASB	158
C 7	Mass Fragmentation of DTASB	159
C 8	Mas Spectrum of DEASB	159
C 9	Mass Fragmentation of DEASB	160
C 10	Mas Spectrum of DIPASB	160
C 11	Mass Fragmentation of DIPASB	161
C 12	Mas Spectrum of DCLASB	161
C 13	Mass Fragmentation of DCLASB	162
C 14	Mas Spectrum of DBRASB	162
C 15	Mass Fragmentation of DBRASB	163
C 16	Mas Spectrum of DMeOSB	163
C 17	Mass Fragmentation of DMeOSB	164
C 18	Mas Spectrum of DNNMASB	164
C 19	Mass Fragmentation of DNNMASB	165
D 1	UV-Vis Spectrum of SBDTC	166

D 2	UV-Vis Spectrum of DBA	166
D 3	UV-Vis Spectrum of DBASB	166
D 4	UV-Vis Spectrum of NiDBASB	166
D 5	UV-Vis Spectrum of CuDBASB	167
D 6	UV-Vis Spectrum of FeDBASB	167
D 7	UV-Vis Spectrum of CdDBASB	167
D 8	UV-Vis Spectrum of ZnDBASB	167
D 9	UV-Vis Spectrum of DCNMA	168
D 10	UV-Vis Spectrum of DCNMASB	168
D 11	UV-Vis Spectrum of NiDCNMASB	168
D 12	UV-Vis Spectrum of CuDCNMASB	168
D 13	UV-Vis Spectrum of FeDCNMASB	169
D 14	UV-Vis Spectrum of CdDCNMASB	169
D 15	UV-Vis Spectrum of ZnDCNMASB	169
D 16	UV-Vis Spectrum of DTA	169
D 17	UV-Vis Spectrum of DTASB	170
D 18	UV-Vis Spectrum of NiDTASB	170
D 19	UV-Vis Spectrum of CuDTASB	170
D 20	UV-Vis Spectrum of FeDTASB	170
D 21	UV-Vis Spectrum of CdDTASB	171
D 22	UV-Vis Spectrum of ZnDTASB	171
D 23	UV-Vis Spectrum of DEA	171
D 24	UV-Vis Spectrum of DEASB	171
D 25	UV-Vis Spectrum of NiDEASB	172
D 26	UV-Vis Spectrum of CuDEASB	172

D 27	UV-Vis Spectrum of FeDEASB	172
D 28	UV-Vis Spectrum of CdDEASB	172
D 29	UV-Vis Spectrum of ZnDEASB	173
D 30	UV-Vis Spectrum of DIPA	173
D 31	UV-Vis Spectrum of DIPASB	173
D 32	UV-Vis Spectrum of NiDIPASB	173
D 33	UV-Vis Spectrum of CuDIPASB	174
D 34	UV-Vis Spectrum of FeDIPASB	174
D 35	UV-Vis Spectrum of CdDIPASB	174
D 36	UV-Vis Spectrum of ZnDIPASB	174
D 37	UV-Vis Spectrum of DCLA	175
D 38	UV-Vis Spectrum of CLASB	175
D 39	UV-Vis Spectrum of NiDCLASB	175
D 40	UV-Vis Spectrum of CuDCLASB	175
D 41	UV-Vis Spectrum of FeDCLASB	176
D 42:	UV-Vis Spectrum of CdDCLASB	176
D 43	UV-Vis Spectrum of ZnDCLASB	176
D 44	UV-Vis Spectrum of DBRA	176
D 45	UV-Vis Spectrum of DBRASB	177
D 46	UV-Vis Spectrum of NiDBRASB	177
D 47	UV-Vis Spectrum of CuDBRASB	177
D 48	UV-Vis Spectrum of FeDBRASB	177
D 49	UV-Vis Spectrum of CdDBRASB	178
D 50	UV-Vis Spectrum of ZnDBRASB	178
D 51	UV-Vis Spectrum of DMeO	178

D 52	UV-Vis Spectrum of DMeOSB	178
D 53	UV-Vis Spectrum of NiDMeOSB	179
D 54	UV-Vis Spectrum of CuDMeOSB	179
D 55	UV-Vis Spectrum of FeDMeOSB	179
D 56	UV-Vis Spectrum of CdDMeOSB	179
D 57	UV-Vis Spectrum of ZnDMeOSB	180
D 58	UV-Vis Spectrum of DNNMA	180
D 59	UV-Vis Spectrum of DNNMASB	180
D 60	UV-Vis Spectrum of NiDNNMASB	180
D 61	UV-Vis Spectrum of CuDNNMASB	181
D 62	UV-Vis Spectrum of FeDNNMASB	181
D 63	UV-Vis Spectrum of CdDNNMASB	181
D 64	UV-Vis Spectrum of ZnDNNMASB	181
E 1	Crystal Structure Data for DTA	182
E 2	Crystal Structure Data for DBRA	183
E 3	Crystal Structure Data for DMeO	184
E	Crystal Structure Data for DMeOSB	185
E 5	Crystal Structure Data for NiDCLASB	186
E 6	Crystal Structure Data for NiDTASB	187
E 7	Crystal Structure Data for NiDEASB	188
E 8	Crystal Structure Data for CdDEASB	189
E 9	Crystal Structure Data for ZnDBRASB	190
E 10	Crystal Structure Data for ZnDCLASB	191
E 11	Crystal Structure Data for ZnDEASB	192
E 12	Crystal Structure Data for ZnDIPASB	193

F 1	Pre-screening bar chart for DCNMASB and its metal complexes against bladder cancer cell line type RT-112	194
F 2	Pre-screening bar chart for DTASB and its metal complexes against bladder cancer cell line type RT-112	194
F 3	Pre-screening bar chart for DEASB and its metal complexes against bladder cancer cell line type RT-112	195
F 4	Pre-screening bar chart for DIPASB and its metal complexes against bladder cancer cell line type RT-112	195
F 5	Pre-screening bar chart for DCLASB and its metal complexes against bladder cancer cell line type RT-112	196
F 6	Pre-screening bar chart for DBRASB and its metal complexes against bladder cancer cell line type RT-112	196
F 7	Pre-screening bar chart for DMeOSB and its metal complexes against bladder cancer cell line type RT-112	197
F 8	Pre-screening bar chart for DNNMASB and its metal complexes against bladder cancer cell line type RT-112	197
F 9	Pre-screening bar chart for DBASB and its metal complexes against bladder cancer cell line type EJ-28	198
F 10	Pre-screening bar chart for DCNMASB and its metal complexes against bladder cancer cell line type EJ-28	198
F 11	Pre-screening bar chart for DTASB and its metal complexes against bladder cancer cell line type EJ-28	199
F 12	Pre-screening bar chart for DEASB and its metal complexes against bladder cancer cell line type EJ-28	199
F 13	Pre-screening bar chart for DIPASB and its metal complexes against bladder cancer cell line type EJ-28	200
F 14	Pre-screening bar chart for DCLASB and its metal complexes against bladder cancer cell line type EJ-28	200
F 15	Pre-screening bar chart for DBRASB and its metal complexes against bladder cancer cell line type EJ-28	201
F 16	Pre-screening bar chart for DMeOSB and its metal complexes against bladder cancer cell line type EJ-28	201

F 17	Pre-screening bar chart for DNNMASB and its metal complexes against bladder cancer cell line EJ-28	202
F 18	The percentage of living (RT-112) cells after treatment with different concentrations of CuDTASB complex to determine the IC ₅₀ value	202
F 19	The percentage of living cells (RT-112) after treatment with different concentrations of CuDEASB complex to determine the IC ₅₀ value	202
F 20	The percentage of living cells (RT-112) after treatment with different concentrations of CuDIPASB complex to determine the IC ₅₀ value	203
F 21	The percentage of living cells (RT-112) after treatment with different concentrations of CuDCLASB complex to determine the IC ₅₀ value	203
F 22	The percentage of living cells (RT-112) after treatment with different concentrations of CuDBRASB complex to determine the IC ₅₀ value	203
F 23	The percentage of living cells (RT-112) after treatment with different concentrations of CuDMeOSB complex to determine the IC ₅₀ value	204
F 24	The percentage of living cells (RT-112) after treatment with different concentrations of FeDMeOSB complex to determine the IC ₅₀ value	204
F 25	The percentage of living cells (RT-112) after treatment with different concentrations of CuDNNMASB complex to determine the IC ₅₀ value	204
F 26	The percentage of living cells (EJ-28) after treatment with different concentrations of CuDTASB complex to determine the IC ₅₀ value	205
F 27	The percentage of living cells (EJ-28) after treatment with different concentrations of CuDEASB complex to determine the IC ₅₀ value	205
F 28	The percentage of living cells (EJ-28) after treatment with different concentrations of CuDIPASB complex to determine the IC ₅₀ value	205
F 29	The percentage of living cells (EJ-28) after treatment with different concentrations of ZnDTASB complex to determine the IC ₅₀ value	206
F 30	The percentage of living cells (EJ-28) after treatment with different concentrations of ZnDEASB complex to determine the IC ₅₀ value	206
F 31	The percentage of living cells (EJ-28) after treatment with different concentrations of CuDCLASB complex to determine the IC ₅₀ value	206
F 32	The percentage of living cells (EJ-28) after treatment with different concentrations of CuDBRASB complex to determine the IC ₅₀ value	207

- F 33 The percentage of living cells (EJ-28) after treatment with different concentrations of CuDMeOSB complex to determine the IC₅₀ value 207
- F 34 The percentage of living cells (EJ-28) after treatment with different concentrations of FeDMeOSB complex to determine the IC₅₀ value 207
- F 35 The percentage of living cells (EJ-28) after treatment with different concentrations of CuDNNMASB complex to determine the IC₅₀ value 208



LIST OF ABBREVIATIONS

SBBTC	S-benzylthiocarbamate
DBA	Dibenzalacetone
DCNMA	Dicinnamalacetone
DTA	Di- <i>p</i> -tolylacetone
DEA	Di- <i>p</i> -ethylbenzalacetone
DIPA	Di- <i>p</i> -isopropylbenzalacetone
DCLA	Di- <i>p</i> -chlorobenzalacetone
DBRA	Di- <i>p</i> -bromobenzalacetone
DMeO	Di- <i>p</i> -methoxybenzalacetone
DNNMA	Di- <i>p</i> -N,N-dimethylaminobenzalacetone
RPMI	Roswell Park Memorial Institute medium
FBS	Fetal bovine serum
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
PBS	Phosphate-buffered saline
DMSO	Dimethylsulphoxide
FT-IR	Fourier Transform Infrared
NMR	Nuclear Magnetic Resonance
MS	Mass spectrometry
ICP-OES	Inductively Coupled Plasma Optical Emission Spectrometry
UV-Vis	Ultraviolet-Visible
RT-112	Minimally-invasive human bladder carcinoma cell line
EJ-28	Invasive human bladder carcinoma cell line
IC ₅₀	Inhibition concentration at 50%
ELISA	Enzyme-linked immunosorbent assay
XRD	X-ray diffraction
SC-XRD	Single Crystal X-ray Diffraction

CHAPTER 1

INTRODUCTION

1.1 General

Medicinal bioinorganic chemistry field blossoming inspired many worldwide researchers to design and innovate metal-based drugs to be used as anticancer drugs. Therefore, using transition metals has outweigh the organic-based drugs because of transition metals have wide range of oxidation and coordination numbers, redox states, tuneable kinetics and thermodynamics, and structural and geometries diversity of the substituted ligands (van Rijt & Sadler, 2009). The discovery of cisplatin as anticancer, about 45 years ago, has making a breakthrough in medicinal inorganic chemistry field as well as in our understandings to the disease and treatment approaches. The organic ligands which effectively bonded with metal ions enhanced the overall efficiency and also driving the innovation in therapy and disease diagnosis areas. Besides, increasing of therapeutic compounds potency and limiting their side-effects is a common goal in the field of medicinal chemistry (Jones *et al.*, 2014). To achieve this goal, compounds are developed to target the disease site or activated by the disease of specific biological process. The metal complexes which containing the targeting functions or bioactive ligands or agents activated by specific enzymes provide a new avenues in drug development (Chiang *et al.*, 2012). Nowadays, after more than 30 years from the improvement of using cisplatin as a powerful chemotherapeutic agent, still it is the best-selling anticancer drug in the world. It is used as chemotherapeutic agent to treat many types of cancer such as bladder, ovarian, head and neck, lymphomas and cervical cancers. Over many past decades, cisplatin and its derivatives have been ensured as powerful anticancer agents, while, only two of them (oxaliplatin and carboplatin) have been used clinically worldwide. Unfortunately, there are some obstacles side-effects against current platinum drugs such as (van Rijt & Sadler, 2009):-

- Limited efficiency because they are efficient for limited cancer types.
- Some types of tumors may have acquired or intrinsic resistance.
- They have many side-effects like, kidney toxicity, bone marrow suppression and nausea.

Therefore, there is a big need to discover new compounds to treat many types of cancer with less side-effects better than cisplatin and its derivatives. New anticancer metal based compounds development is important challenge for many inorganic chemists to face the fact that after more than four decades of researches in anticancer field there are few compounds clinically used as anticancer drug. Based on metal-based anticancer action mode, metal anticancer compounds can be categorized into five categories (Gianferrara *et al.*, 2009):-

- (1) The metal in any compound may has the functional role and bind with the biological target.
- (2) The central metal may has structural role and bind through non-covalent bond with the biological target.
- (3) The metal may acts as a good carrier for the active ligands which delivered in vivo.
- (4) The metal compound may acts like catalyst.
- (5) The metal compound may behaves as a photo-sensitizer or photoactive.

It is known that the fourth most common cancer among men is bladder cancer. Recent diagnostic data on this disease showed that men diagnostic four times more than women. Older people are most affected by bladder cancer than young people. 90% of people suffer from bladder cancer are older than 55 years old. The average age of people who diagnosed with bladder cancer is 73 years old (Fosså *et al.* 2008; Jacobs *et al.* 2010; Tiwari & Roy, 2012). Recent therapy of bladder cancer are Cisplatin, Methotrexate, Gemcitabine, Mitomycin, Vinblastine, Doxorubicin, Carboplatin, Docetaxel, Paclitaxel, 5-Fluorouracil (5-FU) and its derivatives (Edson Pontes, 1994; Galsky & Bajorin, 2007; Kaufman *et al.*, 2009; Oosterlinck *et al.*, 2002). They are general therapy and have many disadvantages such as expensive, difficult to synthesised, only 25% response to the treatment and many side effects of chemotherapy like nausea and vomiting, loss of appetite, hair loss, mouth sores, diarrhea or constipation, increased risk of infections (because of shortage of white blood cells), bleeding or bruising after minor cuts or injuries due to a shortage of blood platelets and fatigue because of a shortage of red blood cells (Dasari & Bernard Tchounwou, 2014; Georg *et al.*, 2012; Koya *et al.*, 2006).

Metal-containing drugs have been used to treat many diseases. The most famous one is cisplatin, used in late 1978, which is the most effective anticancer drug in the world (Jemal *et al.*, 2009; Swarts *et al.*, 2008). Cisplatin success has been motivate many researcher in the past few decades to try another transition metals in term of alternative searching in metal-base chemotherapeutic area (Jakupec *et al.*, 2008). There is an urgent issue to synthesise new drugs with less side effects and better selectivity, activity and bioavailability to treat different types of cancer diseases. Furthermore, discovering new drugs with non platin metal centre might open new way to develop useful drugs with fewer side effects (Marcon *et al.*, 2002; Ronconi *et al.*, 2006). There are many articles highlighted and explained in details the effect of metal complexes potential in designing of novel drugs (Fricker, 2007; Haas & Franz, 2009; Hambley, 2007; Meggers, 2009; Ronconi & Sadler, 2007; Thompson & Orvig, 2006).

Metal centre in transition metal complexes has intrinsic nature, accessible redox state, distinctive coordination modes, and tuneable kinetic and thermodynamic properties drive the transition metal complexes to add more potential advantages more than the organic ligand in the complexes (van Rijt & Sadler, 2009). Furthermore, metal reactivity in the complexes not only controlled by ligands but also the ligands play important roles in the biological activity (Gianferrara *et al.*, 2009). In the few last decades there were a great expansion researches happened in the field of coordination

chemistry of nitrogen-sulphur containing Schiff bases compounds such as thiosemicarbazides, dithiocarbazates and their organic derivatives (Akbar Ali *et al.*,1974; Beraldo, 2004; Pelosi, 2010). Transition metal complexes derived from Schiff bases have been played an important role to develop coordination chemistry. Furthermore, the synthesis and application of Schiff bases and their metal complexes add more attention on this area. Schiff bases can be synthesized by the condensation reaction between aliphatic or aromatic aldehydes or ketones and primary amines. The yielded imine ($R-C=N-R'$) can be used as a chelating ligands for the metal complexes preparation which are useful and can be used in many biological and industrial applications (Kumar *et al.*,2009; Soliman *et al.*,2007). This type of Schiff bases possess two types of donor atoms soft nitrogen and hard sulphur. They have the ability to act as a good chelating agent for various transition metals (Mohamed *et al.*,2009). The bioactivity and flexibility of sulphur and nitrogen containing ligands associated with the presence of both thioamino ($-(C=S)-NH-$) and imino ($-HC=N-$) in their structures moieties (Stringer *et al.*, 2011). Many advantages can be gain from synthesizing these metal complexes such as: chelating of metals with such Schiff bases enhances their biological activity, easy preparation and low cost (Perrin & Chang, 2016).

1.2 Dibenzalacetone Ketones

Aldol condensation reaction like Grignard reaction both are useful carbon-carbon bond-forming organic reaction. Aldol condensation reaction can be used to synthesize unsaturated ketones by reacting aliphatic or aromatic aldehyde with ketone in the presence of mineral acid or alkaline base. This type of reaction is usually used in organic reaction to form bigger ketones with C-C bonds (Carey *et al.*, 2008). This type of reaction contains two steps the first step called Aldol reaction while the second step called elimination reaction for both acid and base Aldol condensation (Carey *et al.*, 2000). Base catalyzed Aldol condensation can be proceeds by using sodium hydroxide or potassium hydroxide.

Dibenzalacetone is a conjugated symmetric chalcone contains two benzene rings connected by unsaturated aliphatic chain with carbonyl group as shown in Figure 1.1.




Figure 1.1 : General chemical structure of dibenzalacetone

Table 1.1 represents dibenzalacetone derivatives.

Table 1.1 : Dibenzalacetone derivatives used in this study

X	Compound name	Abbreviation	Reference
H	Dibenzalacetone	DBA	(Conard <i>et al.</i> , 1932)
CH ₃	Di- <i>p</i> -tolylacetone	DTA	(Arshadet <i>et al.</i> , 2008)
C ₂ H ₅	Di- <i>p</i> -ethylbenzalacetone	DEA	New compound
CH(CH ₃) ₂	Di- <i>p</i> -isopropylbenzalacetone	DIPA	New compound
Cl	Di- <i>p</i> -chlorobenzalacetone	DCLA	(Butcher <i>et al.</i> , 2007)
Br	Di- <i>p</i> -bromobenzalacetone	DBRA	New compound
OCH ₃	Di- <i>p</i> -methoxybenzalacetone	DMeO	(Handani <i>et al.</i> , 2008)
N(CH ₃) ₂	Di- <i>p</i> -N,N-dimethylbenzalacetone	DNNMA	New compound

Unsymmetrical chalcones, type from flavonoids family, are naturally occurring compounds in many edible plants such as fruits, spices and vegetables which are non-toxic to normal cells. While, symmetrical chalcones like dibenzalacetone and dicinnamalacetone are not naturally occurring compounds. Dibenzalacetone can be synthesized by using Aldol condensation from the reaction between two moles of benzaldehyde or its derivatives and one mole of acetone (Youg *et al.*, 2016). Figure 1.2 explains the reaction mechanism of base catalyzed Aldol condensation to synthesized dibenzalacetone ketone in the following main steps (Kim *et al.*, 2016; Perrin *et al.*, 2016):-

- First step: - Deprotonation of acetone by potassium hydroxide or sodium hydroxide and produce nucleophilic enolate.
- Second step: - The nucleophile attacks the electrophile which is benzaldehyde or its derivatives to give alkoxide.
- Third step: - Protonation of alkoxide to produce neutral hydroxylketone.
- Fourth step: - Deprotonation again of hydroxyl-ketone to make nucleophilic enolate (hydroxyenolate).
- Fifth step: - Elimination of hydroxide ion to produce benzalacetone (monoaddition).
- Sixth step: - Repeat steps one to five again to produce the final product dibenzalacetone or its derivatives.




Figure 1.2 : Base catalyzed Aldol condensation mechanism (Kim *et al.*, 2016)

Dibenzalacetone derivatives can be synthesized by using benzaldehyde derivatives instead of un-substituted benzaldehyde. Dibenzalacetone or dibenzylideneacetone is used as an ingredient in sunscreen cream and also as a ligand in organometallic chemistry in the synthesis of palladium(0) complexes (Ogasawara *et al.*, 2001). Para substituted dibenzalacetone can be synthesized by the following Aldol condensation procedure with para substituted benzaldehyde. In the same manner, dicinnamalacetone (Figure 1.3) can be synthesized by using also base catalyzed Aldol condensation with using cinnamaldehyde instead of benzaldehyde.




Figure 1.3 : Chemical structure of dicinnamalacetone DCNMA (da Silva *et al.*, 2018)

These ketones have many features:-

- These compounds are symmetrical chalcones.
- These compounds have long double-single bond conjugation system.
- Many types of functional groups can be substituted on the benzene ring.
- By varying the number of substituted group and the type of substituted group on the two benzene rings it is easy to direct the electron density.

1.3 Dithiocarbazate

Dithiocarbazate compounds are sulphur-nitrogen containing compounds which have the structural analogy to semicarbazides, thiosemicarbazides and carbazates as shown in Figure 1.4.




Figure 1.4 : Molecular structure of (a) semicarbazide, (b) carbazate, (c) thiosemicarbazide and (d) dithiocarbazate

The origin of this type of organic compounds is not well-known but the earliest publication on these compounds was made on 1905 (Dunlap, 1905) who synthesized Schiff base derived from phthalic anhydride and phenylsemicarbazide. In 1946 Domagk studied the antitubercular activity of some thiosemicarbazide derivatives (Domagk *et al.*, 1946). Another important finding in 1970 it was reported on the cytotoxicity of thiosemicarbazide derivatives which were synthesized from thiosemicarbazide and aminopyridine-2-carboxaldehyde (Meldrum *et al.*, 1970). The first publication on dithiocarbazate derivatives was reported in the chemistry of their metal complexes (Ali *et al.*, 1972).

Dithiocarbazate is an organic amine containing two nitrogen atoms and two sulphur atoms as shown in Figure 1.5. Ali and Livingstone was first to review on the chemistry of this type of organic compound which was used to synthesize different compounds of Schiff bases (Akbar *et al.*, 1974). Since then, many derivatives of dithiocarbazate compounds had been synthesized and applied in different applications.

The researchers in this field mostly focused on S-benzyl and S-methyldithiocarbazate (Ali *et al.*, 1978; Rao *et al.*, 1965; Tofazzal *et al.*, 2000) while the others studied recently (Antony *et al.*, 2014; Begum *et al.*, 2015a; Begum *et al.*, 2015b; Low *et al.*, 2016; Mirza *et al.*, 2014).

1.4 Schiff bases

Schiff base has the general chemical structure as shown in the Figure1.5. It is mainly produced from reacting primary amine with ketone or aldehyde.




Figure 1.5 : Chemical structure of Schiff base

Many nitrogen-sulphur Schiff bases have been synthesized from the condensation of dithiocarbamate derivatives with aliphatic and aromatic aldehydes and ketones. Dithiocarbamate Schiff bases have tautomeric resonance which is called thione-thiol resonance as shown in Figure1.6 (Krasowska *et al.*, 2010).





Figure 1.6 : Thione-Thiol tautomerism

Thiosemicarbazide Schiff bases coordinate with transition metal ions in both thione and thiol forms (De Lima *et al.*, 1999). In the same manner, dithiosemicarbazide Schiff bases appear in the thione form when coordinate with transition metal complexes (Hossain *et al.*, 1996).

In this study, nine Schiff bases have been synthesised from reacting SBDTC with dibenzalacetone, dibenzalacetone derivatives and dicinnamalacetone. The reaction between SBDTC and the synthesised ketones was catalyzed by hydrochloric acid or acetic acid. The reaction scheme illustrated in Figure1.7.



R	Ketone	Schiff Base
- H	Dibenzalacetone (DBA)	DBASB
- CH ₃	Di- <i>p</i> -tolylacetone (DTA)	DTASB
- C ₂ H ₅	Di- <i>p</i> -ethylbenzalacetone (DEA)	DEASB
- CH(CH ₃) ₂	Di- <i>p</i> -isopropylbenzalacetone (DIPA)	DEASB
- Cl	Di- <i>p</i> -chlorobenzalacetone (DCLA)	DCLASB
- Br	Di- <i>p</i> -bromobenzalacetone (DBRA)	DBRASB
- OCH ₃	Di- <i>p</i> -methoxybenzalacetone (DMeO)	DMeOSB
- N(CH ₃) ₂	Di- <i>p</i> -N,N-dimethylaminobenzalacetone (DNNMA)	DNNMASB

Figure 1.7 : Reaction scheme of Schiff bases synthesis and chemical structure of the synthesized Schiff bases

1.5 Metal complexes

It is well known that the drug action can be accelerated by metal complexes and therapeutic efficiency can be enhanced by the coordination with transition metal ions (Navarro *et al.*, 2004; Raman *et al.*, 2008; Sánchez-Delgado *et al.*, 1996). Biological activity of metal complexes highly depends on the transition metal and the donor ligand. The observation from different published articles on metal complexes of NS donor Schiff bases showed that nickel, copper and zinc complexes have good activity against Human T-lymphoblastic leukemia cell (CEM-SS) with low CD₅₀ values 2.0-3.4 μg cm⁻³. While cadmium complexes showed moderate activity against cervical cancer cells (HELA) and CEM-SS cell with CD₅₀ values 4.0 and 4.95 μg cm⁻³, respectively (Tarafder *et al.*, 2002a).

To summarize briefly, this thesis aimed to study the effect of aromatic dithiocarbamate (SBDTC), double bond-single bond conjugation system (highly conjugated ketones), vital transition metals and the effect of functional group substituted on para position of both benzene rings on the cytotoxicity of these metal complexes against two types of bladder cancer cell lines which are invasive human bladder carcinoma cell line (EJ-

28) and minimally invasive human bladder carcinoma cell line (RT-112). The target metal complexes were synthesized and characterized. The five divalent transition metals were chosen in this study due to their biological lability and inertness (Figure 1.8). While, Cd(II) and Zn(II) were the most labile (Blusch *et al.*, 2013; Karlin, 2012). Their vital presence in biological systems and many enzymes, as outlined previously, were also chosen as important aspects in their selection in this study.




Figure 1.8 : General chemical structure of the transition metal complexes

Table 1.2 shows the metal complexes which have been synthesised in this study.

Table 1.2 : The synthesised transition metal complexes

X	M	Name	X	M	Name
Hydrogen H	Ni(II)	NiDBASB	Methyl CH ₃	Ni(II)	NiDTASB
	Cu(II)	CuDBASB		Cu(II)	CuDTASB
	Fe(II)	FeDBASB		Fe(II)	FeDTASB
	Cd(II)	CdDBASB		Cd(II)	CdDTASB
	Zn(II)	ZnDBASB		Zn(II)	ZnDTASB
Ethyl C ₂ H ₅	Ni(II)	NiDEASB	isopropyl CH(CH ₃) ₂	Ni(II)	NiDIPASB
	Cu(II)	CuDEASB		Cu(II)	CuDIPASB
	Fe(II)	FeDEASB		Fe(II)	FeDIPASB
	Cd(II)	CdDEASB		Cd(II)	CdDIPASB
	Zn(II)	ZnDEASB		Zn(II)	ZnDIPASB
Chloro Cl	Ni(II)	NiDCLASB	Bromo Br	Ni(II)	NiDBRASB
	Cu(II)	CuDCLASB		Cu(II)	CuDBRASB
	Fe(II)	FeDCLASB		Fe(II)	FeDBRASB
	Cd(II)	CdDCLASB		Cd(II)	CdDBRASB
	Zn(II)	ZnDCLASB		Zn(II)	ZnDBRASB
Methoxy OCH ₃	Ni(II)	NiDMeOSB	N,N- dimethylamino N(CH ₃) ₂	Ni(II)	NiDNNMASB
	Cu(II)	CuDMeOSB		Cu(II)	CuDNNMASB
	Fe(II)	FeDMeOSB		Fe(II)	FeDNNMASB
	Cd(II)	CdDMeOSB		Cd(II)	CdDNNMASB
	Zn(II)	ZnDMeOSB		Zn(II)	ZnDNNMASB

1.6 Cytotoxicity

The biological activity of a chemical species can be explained by experimental and computational methods. There are a lot of theoretical studies about the determination of chemical activity. Generally, quantum chemical descriptors are used to determine the ranking of biological activities (Sayin & Karakas, 2013). The examples of these parameters include the highest occupied molecular orbital energies (HOMO), the lowest unoccupied molecular orbital energies (LUMO), the energy gap between LUMO and HOMO, hardness or softness of the molecules or atoms and the global electronegativity. The biological activities closely depend on the separation of the LUMO and HOMO in a molecule. The bending ability of an inhibitor to the appropriate molecule will increase with the increase of the HOMO and decrease of the LUMO of complex ions. This due to the ability of electrons to transfer to the acceptor molecule and the strong electron accepting ability of the molecules. The smaller the energy gap between HOMO and LUMO, the more active the molecule is in the term of biological properties. This because the electrons are easily excited from the lower energy orbital to higher energy orbital (Zhang *et al.*, 2012). Besides that, soft complexes (complexes in which sulphur atoms act as donor atoms) have a small energy gap between the molecular orbital and can interact easily with biological molecules. Hence, the biological activity is increased with the increase of softness of the complexes. Cytotoxicity of some sulphur-nitrogen ligands and their metal complexes is based on four main criteria. Firstly, the complex should be reasonably labile. Zinc and cadmium complexes are the most labile with d^{10} configurations. Secondly, the metal chelate should have reasonably high thermodynamic stability. The metals used on complexation should be (b) class metals (4d metals), in particular palladium and platinum due to its similarity to cisplatin, a common anticancer drug used in cancer treatment. Complexes or ligands with sulphur acting as donor atoms are the most likely to be effective drugs. This is because they allow for lipid solubility of the stable metal complexes (Ali *et al.*, 2011).

Besides, some studies on the behaviour of bladder cancer cells shown that acidic environments help bladder cancer cells grow. From this point, synthesizing of alkaline or neutral metal complexes may raises pH level and make the body more alkaline and cure or prevent bladder cancer. While, some *in vitro* studies on cancer cells do not represent the complex acidity or basicity nature of how tumors behave *in vivo* or in the human body (Ali & Livingstone, 1974).

1.7 Problem statements

Globally, bladder cancer is the fourth most common type of cancer in men. General therapy such as Cisplatin, Methotrexate, Gemcitabine, Mitomycin, Vinblastine, Doxorubicin, Carboplatin, Docetaxel, Paclitaxel, 5-Fluorouracil (5-FU) and its derivatives are still used in the treatment of bladder cancer and also they are used to treat many types of cancer. The side effects of these chemotherapies include nausea, vomiting, loss of appetite, hair loss, mouth sores, diarrhea or constipation, increased risk of infections (because of a shortage of white blood cells), bleeding or bruising

after minor cuts or injuries (due to a shortage of blood platelets), fatigue (because of a shortage of red blood cells) are very severe. Thus there is a need to identify, efficacious anti-cancer drugs that are less toxic. Besides, the electron density can be directed to the complex centre which is transition metal by using symmetrical chalcones better than using unsymmetrical chalcones. Therefore, the cytotoxicity of the synthesized metal complexes solution dissolved in DMSO as a solvent was determined which are non-toxic due to the nontoxicity of dibenzalacetone which are chalcones. The advantage of using these aromatic chalcones is to synthesise chalcones substituted with many functional groups after studying the effect of functional group against bladder cancer cells. The cytotoxicity of dithiocarbamate metal complexes have been studied by many researchers against many types of cancer. Unfortunately, there is a very little research on using dithiocarbamate complexes as anticancer agents against bladder cancer. The previous works on testing dithiocarbamate complexes against different types of cancer cells showed significant activity. The previous studies showed that the metal complexes of Cu^{2+} , Ni^{2+} , Cd^{2+} , and Zn^{2+} were active compounds against cancer cells. In the same manner, these metal complexes derived from SBDTC and symmetrical dibenzalacetone are expected to show significant activity against bladder cancer cells due to their lipophilicity and ability to penetrate lipid permeable membrane of cancer cell. Then, ligands (Schiff base) used to transport and address the compounds to the specific site of cancer cell. This research will not study the toxicity of the synthesised compounds against normal bladder cells because of the slow growth of normal bladder cells and the concentration of the tested compounds is less than the toxic concentration of dithiocarbamate metal complexes which is more than 10 μM .

1.8 Objectives

This study was conducted to synthesise and fully characterize dithiocarbamate derived from S-benzyl dithiocarbamate and highly conjugated ketones and their metal complexes. Besides, this study aimed to test the cytotoxicity activity against two types of bladder cancer cell lines EJ28 & RT112. The toxicity of the synthesised complexes will not be tested in this study because normal bladder cells grow at a much slower rate in induced conditions compared to cancer cells. Besides, bladder cancer cells mutate and do not typically like normal cells and making the test inaccurate. Secondly, normal bladder cells tend to get contaminated and die very easily compared to cancer cells which means sustaining enough cells for analysis is difficult. The main objectives of this study include:

- To synthesise and characterize nine symmetrical ketones with highly conjugated system via base catalysed Aldol condensation.
- To synthesise and characterize nine novel Schiff bases derived from the above symmetrical ketones and S-benzyl dithiocarbamate by acid catalysed condensation.
- To synthesise and characterize 45 novel metal complexes derived from the above Schiff bases and five divalent transition metals which are Ni(II), Cu(II), Fe(II), Zn(II) and Cd(II).
- To elucidate the cytotoxic activity of the Schiff bases and their metal complexes against two types from bladder cancer cell lines (EJ28 & RT112).

REFERENCES

- AlKadhimi, AJ& AL, Jasim. (2012). Synthesis and Antibacterial Evaluation of Bis - pyrrolidinyl Ketones. *Pharmaceutical, Biological and Chemical Sciences*, 3(1), 608–921.
- Abirami, M., & Nadaraj, V. (2014). Chemistry and biological importance of copper Schiff base complexes. *International Journal of Scientific Research and Reviews*, 7(2), 103-108.
- Ahcene, B., Xavier, R., Jean, B., Boumendjel, A., Ronot, X., & Boutonnat, J. (2009). Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs. *Current Drug Targets*, 10(4), 363–371.
- Akbar Ali, M., & Bose, R. (1977). Metal complexes of schiff bases formed by condensation of 2-methoxybenzaldehyde and 2-hydroxybenzaldehyde with S-benzylidithiocarbazate. *Journal of Inorganic and Nuclear Chemistry*, 39(2), 265–269.
- Akbar Ali, M., Huq Mirza, A., Nazimuddin, M., Rahman, H., & Butcher, R. J. (2002). The preparation and characterization of mono- and bis-chelated cadmium(II) complexes of the di-2-pyridylketone Schiff base of S-methyldithiocarbazate (Hdpksme) and the X-ray crystal structure of the $[\text{Cd}(\text{dpksme})_2] \cdot \text{MeOH}$ complex. *Transition Metal Chemistry*, 27(3), 268–273.
- Akbar Ali, M., & Livingstone, S. E. (1974). Metal complexes of sulphur-nitrogen chelating agents. *Coordination Chemistry Reviews*, 13(2–3), 101–132.
- Akbar Ali, M., Mirza, A. H., Bujang, F. H., Hamid, M. H. S. A., & Bernhardt, P. V. (2006). Synthesis, characterization and X-ray crystallographic structural study of copper(II) and nickel(II) complexes of the 2-quinoline carboxaldehyde Schiff base of S-methyldithiocarbazate (Hqaldsme). *Polyhedron*, 25(17), 3245–3252.
- Akbar Ali, M., Mirza, A. H., Nazimuddin, M., Ahmed, R., Gahan, L. R., & Bernhardt, P. V. (2003). Synthesis and characterization of mono- and bis-ligand zinc(II) and cadmium(II) complexes of the di-2-pyridylketone Schiff base of S-benzyl dithiocarbazate (Hdpksbz) and the X-ray structures of the $[\text{Zn}(\text{dpksbz})_2]$ and $[\text{Cd}(\text{dpksbz})\text{NCS}]_2$ complexes. *Polyhedron*, 22(11), 1471–1479.
- Akbar Ali, M., & Tarafdar, M. T. H. (1977). Metal complexes of sulphur and nitrogen-containing ligands: Complexes of s-benzylidithiocarbazate and a schiff base formed by its condensation with pyridine-2-carboxaldehyde. *Journal of Inorganic and Nuclear Chemistry*, 39(10), 1785–1791.
- Ali, M. A., Hj Abu Bakar, H. J., Mirza, A. H., Smith, S. J., Gahan, L. R., & Bernhardt, P. V. (2008). Preparation, spectroscopic characterization and X-ray crystal and molecular structures of nickel(II), copper(II) and zinc(II) complexes of the Schiff base formed from isatin and S-methyldithiocarbazate (Hisa-sme).

Polyhedron, 27(1), 71-79.

- Ali, M. A., Livingstone, S. E., & Phillips, D. J. (1972). Metal chelates of dithiocarbazic acid and its derivatives. III. Complexes of the tridentate schiff base [α]-N-Methyl-S-methyl-[β]-N-(2-pyridyl)methylendithiocarbazate with some 3d metal ions. *Inorganica Chimica Acta*, 6, 11–16.
- Ali, M. A., Mirza, A. H., Bakar, H. J. H. A., & Bernhardt, P. V. (2011). Preparation and structural characterization of nickel(II), cobalt(II), zinc(II) and tin(IV) complexes of the isatin Schiff bases of S-methyl and S-benzylidithiocarbazates. *Polyhedron*, 30(4), 556–564.
- Ali, M. A., & Teoh, S. G. (1978). Magnetic and spectroscopic studies on metal complexes of some oxygen-nitrogen and sulphur-nitrogen chelating agents. *Journal of Inorganic and Nuclear Chemistry*, 40(3), 451–458.
- Alomar, K., Landreau, A., Kempf, M., Khan, M. A., Allain, M., & Bouet, G. (2010). Synthesis, crystal structure, characterization of zinc(II), cadmium(II) complexes with 3-thiophene aldehyde thiosemicarbazone (3TTSCH). Biological activities of 3TTSCH and its complexes. *Journal of Inorganic Biochemistry*, 104(4), 397–404.
- Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G., & Camalli, M. (1994). SIRPOW .92 – a program for automatic solution of crystal structures by direct methods optimized for powder data. *Journal of Applied Crystallography*, 27(3), 435–436.
- Antony, R., Theodore David Manickam, S., Karuppasamy, K., Kollu, P., Chandrasekar, P. V., & Balakumar, S. (2014). Organic–inorganic hybrid catalysts containing new Schiff base for environment friendly cyclohexane oxidation. *RSC Advances*, 4(81), 42816–42824.
- Arshad, M. N., Tahir, M. N., Asghar, M. N., Khan, I. U., & Ashfaq, M. (2008). (1 E ,4 E)-1,5-Bis(4-methylphenyl)penta-1,4-dien-3-one. *Acta Crystallographica Section E Structure Reports Online*, 64(8), o1413–o1413.
- Asiri, A. M., & Badahdah, K. O. (2007). Synthesis of some new anils: Part 1. Reaction of 2-hydroxy-benzaldehyde and 2-hydroxynaphthaldehyde with 2-aminopyridine and 2-aminopyrazine. *Molecules*, 12(8), 1796-1804.
- Basha, M. T., Chartres, J. D., Pantarat, N., Akbar Ali, M., Mirza, A. H., Kalinowski, D. S., ... Bernhardt, P. V. (2012). Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity. *Dalton Transactions*, 41(21), 6536.
- Begum, M. S., Howlader, M. B. H., Miyatake, R., Zangrando, E., & Sheikh, M. C. (2015)a. Crystal structure of S -hexyl (E)-3-(4-methoxybenzylidene)dithiocarbazate. *Acta Crystallographica Section E Crystallographic Communications*, 71(3), o199–o199.

- Begum, M. S., Zangrando, E., Sheikh, M. C., Miyatake, R., & Hossain, M. M. (2015)b. Crystal structure of S -octyl (E)-3-(4-methoxybenzylidene)dithiocarbazate. *Acta Crystallographica Section E Crystallographic Communications*, 71(4), o265–o266.
- Begum, M. S., Zangrando, E., Sheikh, M. C., Miyatake, R., Howlader, M. B. H., Rahman, M. N., & Ghosh, A. (2017). Bischelated complexes of a dithiocarbazate N,S Schiff base ligand: synthesis, characterization and antimicrobial activities. *Transition Metal Chemistry*, 42(6), 553–563.
- Bera, P., Kim, C.-H., & Seok, S. Il. (2008). Synthesis, spectroscopic characterization and thermal behavior of cadmium(II) complexes of S-methyldithiocarbazate (SMDTC) and S-benzylidithiocarbazate (SBDTC): X-ray crystal structure of [Cd(SMDTC)3]·2NO₃. *Polyhedron*, 27(17), 3433–3438.
- Bera, P., Kim, C.-H., & Seok, S. Il. (2009). Synthesis, spectroscopy and thermal behavior of new lead(II) complexes derived from S-methyl/benzylidithiocarbazates (SMDTC/SBDTC): X-ray crystal structure of [Pb(SMDTC)(NO₃)₂]. *Inorganica Chimica Acta*, 362(8), 2603–2608.
- Beraldo, H. (2004). Semicarbazones and thiosemicarbazones: Their wide pharmacological profile & clinical applications. *Quimica Nova*, 27(3), 461–471.
- Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K., & Watkin, D. J. (2003). CRYSTALS version 12: software for guided crystal structure analysis. *Journal of Applied Crystallography*, 36(6), 1487-1487.
- Bharti, N., Athar, F., Maurya, M. R., & Azam, A. (2004). Synthesis, characterization and in vitro anti-amoebic activity of new palladium(II) complexes with 5-nitrothiophene-2-carboxaldehyde N(4)-substituted thiosemicarbazones. *Bioorganic and Medicinal Chemistry*, 12(17), 4679–4684.
- Blusch, L. L. K., Hemberger, Y., Pröpper, K., Dittrich, B., Witterauf, F., John, M., ... Wilkins, R. G. (2013). Shriver and Atkins' Inorganic Chemistry. *The Siamese-Twin Porphyrin and Its Copper*. 50, 864.
- Butcher, R. J., Jasinski, J. P., Sarojini, B. K., Yathirajan, H. S., Bindya, S., & Narayana, B. (2007). 1,5-Bis(4-fluorophenyl)penta-1,4-dien-3-one. *Acta Crystallographica Section E Structure Reports Online*, 63(7), o3213–o3214.
- Carey, F. A., & Sundberg, R. J. (2007). Advanced Organic Chemistry Part A: Structure and Mechanisms. Ebook. pp. 135.
- Carey, F. A., & Sundberg, R. J. (2008). Advanced organic chemistry Part B: Reactions and Synthesis. Ebook. pp. 1345.
- Chiang, L., R. Jones, M., L. Ferreira, C., & Storr, T. (2012). Multifunctional Ligands in Medicinal Inorganic Chemistry- Current Trends and Future Directions. *Current Topics in Medicinal Chemistry*, 12(3), 122–144.

- Cory, a H., Owen, T. C., Barltrop, J. a, & Cory, J. G. (1991). Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. *Cancer Communications*.
- Cotton, F. A., & Wilkinson, G. (1972). Advanced Inorganic Chemistry: A Comprehensive Text. In *Advanced Inorganic Chemistry* (pp. 657–669).
- Crouse, K. A., Chew, K. B., Tarafder, M. T. H., Kasbollah, A., Ali, A. M., Yamin, B. M., & Fun, H. K. (2004). Synthesis, characterization and bio-activity of S-2-picolylidithiocarbazate (S2PDTC), some of its Schiff bases and their Ni(II) complexes and X-ray structure of S-2-picolyl- β -N-(2-acetylpyrrole)dithiocarbazate. *Polyhedron*, 23(1), 161–168.
- da Silva, P. S. P., Martín-Ramos, P., Domingos, S. R., Bota de Sousa, M. do C., Arranja, C. T., Sobral, A. J. F. N., & Ramos Silva, M. (2018). On the Performance of Hybrid Functionals for Non-linear Optical Properties and Electronic Excitations in Chiral Molecular Crystals: The Case of Butterfly-Shaped Dicinnamalacetone. *ChemPhysChem.*, 19(1), 82–92.
- Das, S. K., & Roberts, S. B. (2012). Present Knowledge in Nutrition. Present Knowledge in Nutrition: Tenth Edition. pp. 864-923.
- Dasari, S., & Bernard Tchounwou, P. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*, 740, 364-378.
- De Lima, R. L., De Souza Teixeira, L. R., Gomes Carneiro, T. M., & Beraldo, H. (1999). Nickel(II), Copper(I) and Copper(II) Complexes of Bidentate Heterocyclic Thiosemicarbazones. *Journal of the Brazilian Chemical Society*, 10(3), 184–188.
- Dhanaraj, C. J., & Johnson, J. (2015). Spectral, thermal, electrochemical, biological and DFT studies on nanocrystalline Co(II), Ni(II), Cu(II) and Zn(II) complexes with a tridentate ONO donor Schiff base ligand. *Journal of Coordination Chemistry*, 68(140), 2449-2469.
- Domagk, G., Behnisch, R., Mietzsch, F., & Schmidt, H. S. (1946). Über eine neue, gegen Tuberkelbazillen in vitro wirksame Verbindungsklasse. *Die Naturwissenschaften*, 33(10), 315.
- Dunlap, F. L. (1905). The action of phenylsemicarbazide and semicarbazide hydrochloride on pathalic anhydride. *Journal of the American Chemical Society*, 27(9), 1091–1107.
- Edson Pontes, J. (1994). Advanced bladder cancer: options of therapy. *Cancer Chemotherapy and Pharmacology*, 35(S1), S93-S96.
- Fosså, S. D., Loge, J. H., & Dahl, A. A. (2008). Long-term survivorship after cancer: How far have we come?. *In Annals of Oncology*, 19(5), v25-29.

- Fraga, C. G. (2005). Relevance, essentiality and toxicity of trace elements in human health. *Molecular Aspects of Medicine*, 26(4-5), 235-244.
- Fricker, S. P. (2007). Metal based drugs: from serendipity to design. *Dalton Transactions*, 43, 4903-4917.
- Fulmer, G. R., Miller, A. J. M., Sherden, N. H., Gottlieb, H. E., Nudelman, A., Stoltz, B. M., & Goldberg, K. I. (2010). NMR chemical shifts of trace impurities: Common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist. *Organometallics*, 29(9), 2176–2179.
- Galsky, M. D., & Bajorin, D. F. (2007). Chemotherapy for bladder cancer. In *Urological Cancers in Clinical Practice*. pp. 102–123.
- Geary, W. J. (1971). Use of conductivity measurements in organic solvents for the characterization of coordination compounds. *Coordination Chemistry Reviews*, 7(1), 81–122.
- Georg, P., Pötter, R., Georg, D., Lang, S., Dimopoulos, J. C. A., Sturdza, A. E., Dörr, W. (2012). Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. *International Journal of Radiation Oncology Biology Physics*, 82(2), 653–657.
- Ghanbari, Z., Housaindokht, M. R., Izadyar, M., Bozorgmehr, M. R., Eshtiagh-Hosseini, H., Bahrami, A. R., & Khoshkholgh, M. J. (2014). Structure-activity relationship for Fe(III)-salen-like complexes as potent anticancer agents. *The Scientific World Journal*, 2014(Iii), 1–10.
- Ghosh, A., Wondimagegn, T., & Parusel, A. B. J. (2000). Electronic structure of gallium, copper, and nickel complexes of corrole. High-valent transition metal centers versus noninnocent ligands. *Journal of the American Chemical Society*. Gianferrara, T., Bratsos, I., & Alessio, E. (2009). A categorization of metal anticancer compounds based on their mode of action. *Dalton Transactions*, (37), 7588–7598.
- Gottlieb, H. E., Kotlyar, V., & Nudelman, A. (1997). NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. *The Journal of Organic Chemistry*, 62(21), 7512–7515.
- Graminha, A. E., & Sp, S. Ã. O. C. (2010). Complexos de Ru e Pd com bases de Schiff de ditiocarbazatos com interesse bioinorgânico e quimioterápico. *Dissertação De Mestrado*, 144.
- Guggenheim, K. Y. (1995). Chlorosis: the rise and disappearance of a nutritional disease. *The Journal of Nutrition*, 125, 1822-1825.
- Haas, K. L. and Franz, K. J. (2009). Application of metal coordination chemistry to explore and manipulate cell biology. *Chemical Reviews*, 109(10), 4921–4960.

- Hahn, R., Herrmann, W. A., Artus, G. R. J., & Kleine, M. (1995). Biologically relevant metal coordination compounds: MoVIO₂ and nickel(II) complexes with tridentate aromatic schiff bases. *Polyhedron*, 14(20-21), 2953-2960.
- Halcrow, M. A. (2013). Jahn-Teller distortions in transition metal compounds, and their importance in functional molecular and inorganic materials. *Chemical Society Reviews*. Hambley, T. W. (2007). Developing new metal-based therapeutics: challenges and opportunities. *Dalton Transactions*, 43, 4929.
- Handani, S., & Indyah Sulisty, A. (2008). Synthesis of Hydroxyl Radical Scavengers from Benzalacetone and its Derivatives. *Journal of Physical Science*, 19(2), 61-68.
- Hazra, S., Majumder, S., Fleck, M., Koner, R., & Mohanta, S. (2009). Syntheses, structures, absorption and emission properties of a tetraaminodiphenol macrocyclic ligand and its dinuclear Zn(II) and Pb(II) complexes. *Polyhedron*, 28(14), 2871-2878.
- Hossain, M. E., Alam, M. N., Ali, M. A., Nazimuddin, M., Smith, F. E., & Hynes, R. C. (1996a). The synthesis, characterization and bioactivities of some copper(II) complexes of the 2-acetylpyridine schiff bases of s-methyl- and s-benzyl dithiocarbamate, and the x-ray crystal structure of the nitrate(s-benzyl-β-n-(2-acetylpyridyl) methylenedithiocarb. *Polyhedron*, 15(5-6), 973-980.
- Hossain, M. E., Alam, M. N., Begum, J., Akbar Ali, M., Nazimuddin, M., Smith, F. E., & Hynes, R. C. (1996b). The preparation, characterization, crystal structure and biological activities of some copper(II) complexes of the 2-benzoylpyridine Schiff bases of S-methyl- and S-benzyl dithiocarbamate. *Inorganica Chimica Acta*, 249(2), 207-213.
- How, F. N. F., Watkin, D. J., Crouse, K. A., & Tahir, M. I. M. (2007). 2-Naphthylmethyl N-(3-pyridylmethyl-ene)hydrazinecarbodithio-ate. *Acta Crystallographica Section E: Structure Reports Online*, 63(7), o3133-o3134.
- Isam Hussain T. Al-Karkhi. 2011. *Synthesis, Characterization and Bioactivity of New Phosphorous Containing Schiff Bases Prepared From Dithiocarbamate Derivatives and Their Metal Complexes*, PhD Thesis, Universiti Putra Malaysia.
- Islam, M. A.-A.-A.-A., Sheikh, M. C., Mumit, M. A., Miyatake, R., Alam, M. A., & Mondal, M. O. A. (2016). Synthesis, characterization and antimicrobial activity of a bidentate NS Schiff base of S-benzyl dithiocarbamate and its divalent complexes. *Journal of Coordination Chemistry*, 69(23), 3580-3592.
- Islam, M. A. A. A. A., Sheikh, M. C., Mahmud, A. A., Miyatake, R., & Zangrando, E. (2016). Benzyl 3-(3,4,5-trimethoxybenzylidene)dithiocarbamate. *IUCr Data*, 3(1), 1-3.
- Jacobs, B. L., Lee, C. T., & Montie, J. E. (2010). Bladder Cancer in 2010: How Far have We Come? *CA: A Cancer Journal for Clinicians*, 60(4), 244-272.

- Jakupec, M. A., Galanski, M., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008). Antitumour metal compounds: More than theme and variations. *Dalton Transactions*, (2), 183–194.
- Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer Statistics, 2009. *CA: A Cancer Journal for Clinicians*, 59(4), 225–249.
- Jones, M. R., Duncan, D., & Storr, T. (2014). Introduction to Ligand Design in Medicinal Inorganic Chemistry. *Ligand Design in Medicinal Inorganic Chemistry*, 9781118488, 1–8.
- Kapitza, S., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005). The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. *Cancer Letters*, 226(2), 115–121.
- Karlin, K. D. (2012). Progress in Inorganic Chemistry. Progress in Inorganic Chemistry (Vol. 57), pp. 55-129.
- Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009). *Bladder cancer. Lancet*, 374(9685), 239–249.
- Khoo, T. J., Break, M. K. Bin, Crouse, K. A., Tahir, M. I. M., Ali, A. M., Cowley, A. R., & Tarafder, M. T. H. (2014). Synthesis, characterization and biological activity of two Schiff base ligands and their nickel(II), copper(II), zinc(II) and cadmium(II) complexes derived from S-4-picolyldithiocarbazate and X-ray crystal structure of cadmium(II) complex derived from pyr. *Inorganica Chimica Acta*, 413, 68–76.
- Kim, K. C., Moschetta, E. G., Jones, C. W., & Jang, S. S. (2016). Molecular Dynamics Simulations of Aldol Condensation Catalyzed by Alkylamine-Functionalized Crystalline Silica Surfaces. *Journal of the American Chemical Society*, 138(24), 7664–7672.
- Kovala-Demertzi, D., Staninska, M., Garcia-Santos, I., Castineiras, A., & Demertzi, M. A. (2011). Synthesis, crystal structures and spectroscopy of meclufenamic acid and its metal complexes with manganese(II), copper(II), zinc(II) and cadmium(II). Antiproliferative and superoxide dismutase activity. *Journal of Inorganic Biochemistry*, 105(9), 1187-1195.
- Kovala-Demertzi, D., Yadav, P. N., Wiecek, J., Skoulika, S., Varadinova, T., & Demertzi, M. A. (2006). Zinc(II) complexes derived from pyridine-2-carbaldehyde thiosemicarbazone and (1E)-1-pyridin-2-ylethan-1-one thiosemicarbazone. Synthesis, crystal structures and antiproliferative activity of zinc(II) complexes. *Journal of Inorganic Biochemistry*, 100(9), 1558-1567.
- Koya, M. P., Simon, M. A., & Soloway, M. S. (2006). Complications of Intravesical Therapy for Urothelial Cancer of the Bladder. *Journal of Urology*, 175(6), 2004-2010.

- Krasowska, M., Kochel, A., & Filarowski, A. (2010). The conformational analysis of 2-hydroxyaryl Schiff thiosemicarbazones. *CrystEngComm*, 12(6), 1955–1962.
- Kumar, S., Dhar, D. N., & Saxena, P. N. (2009). Applications of metal complexes of Schiff bases-A review. *Journal of Scientific and Industrial Research*, 68(3), 181–187.
- Liu, Y.-T., Lian, G.-D., Yin, D.-W., & Su, B.-J. (2013). Synthesis, characterization and biological activity of ferrocene-based Schiff base ligands and their metal (II) complexes. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 100, 131-137.
- Liu, Y. T., Lian, G. D., Yin, D. W., & Su, B. J. (2012). Synthesis and antimicrobial activity of some novel ferrocene-based Schiff bases containing a ferrocene unit. *Research on Chemical Intermediates*, 38(3–5), 1043–1053.
- Lobana, T. S., Khanna, S., Butcher, R. J., Hunter, A. D., & Zeller, M. (2007). Methyl substituent at C2 carbon of acetophenone thiosemicarbazone induces unusual heterobridging in the [(Ph₃P) Cu(μ-I)₂(μ-S-Haptsc)Cu(PPh₃)] dimer. *Inorganic Chemistry*, 46(15), 5826-5828.
- Low, M. L., Maigre, L., Tahir, M. I. M., Tiekink, E. R. T., Dorlet, P., Guillot, R., Crouse, K. A. (2016). New insight into the structural, electrochemical and biological aspects of macrocyclic Cu(II) complexes derived from S-substituted dithiocarbazate schiff bases. *European Journal of Medicinal Chemistry*, 120, 1–12.
- Mahapatra, D. K., & Bharti, S. K. (2016). Therapeutic potential of chalcones as cardiovascular agents. *Life Sciences*, 148, 154–172.
- Mahapatra, D. K., Bharti, S. K., & Asati, V. (2017). Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. *Current Topics in Medicinal Chemistry*, 17(28).
- Maia, P. I. d. S., Fernandes, A. G. d. A., Silva, J. J. N., Andricopulo, A. D., Lemos, S. S., Lang, E. S., ... Deflon, V. M. (2010). Dithiocarbazate complexes with the [M(PPh₃)₂]⁺(M=Pd or Pt) moiety. Synthesis, characterization and anti-Tripanosoma cruzi activity. *Journal of Inorganic Biochemistry*, 104(12), 1276–1282.
- Marcon, G., Carotti, S., Coronello, M., Messori, L., Mini, E., Orioli, P., Minghetti, G. (2002). Gold(III) complexes with bipyridyl ligands: Solution chemistry, cytotoxicity, and DNA binding properties. *Journal of Medicinal Chemistry*, 45(8), 1672–1677.
- McDowell, L. R. (2003). Minerals in Animal and Human Nutrition. Minerals in Animal and Human Nutrition: Second Edition, pp. 1-644.
- Meggers, E. (2009). Targeting proteins with metal complexes. *Chemical Communications*, (9), 1001.

- Meldrum, B. ., Balzano, E., Gadea, M., & Naquet, R. (1970). Photic and drug-induced epilepsy in the baboon (*Papio papio*): The effects of isoniazid, thiosemicarbazide, pyridoxine and amino-oxyacetic acid. *Electroencephalography and Clinical Neurophysiology*, 29(4), 333–347. [https://doi.org/10.1016/0013-4694\(70\)90041-6](https://doi.org/10.1016/0013-4694(70)90041-6)
- Mirza, A. H., Akbar Ali, M., Bernhardt, P. V., & Asri, I. (2014). Dimeric nickel(II) and copper(II) complexes of the pentadentate N3S2chelating agents derived from S-alkyl/aryl esters of dithiocarbazic acid. *Polyhedron*, 81, 723–727.
- Mohamed, G. G., Omar, M. M., & Ibrahim, A. A. (2009). Biological activity studies on metal complexes of novel tridentate Schiff base ligand. Spectroscopic and thermal characterization. *European Journal of Medicinal Chemistry*, 44(12), 4801–4812.
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*, 65(1–2), 55–63.
- Navarro, M., Vásquez, F., Sánchez-Delgado, R. A., Pérez, H., Sinou, V., & Schrével, J. (2004). Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes. *Journal of Medicinal Chemistry*, 47(21), 5204–5209.
- Nishioka, K., Rice, J. C., Sarma, K., Erdjument-Bromage, H., Werner, J., Wang, Y., & Reinberg, D. (2002). Insights into the role of zinc(II) sites in hydrolytic enzymes: Study of the ZnII/X/(py)₂CO (X = Cl⁻, N³⁻, SO₄²⁻; (py)₂CO=di-2-pyridyl ketone) reaction systems. *Inorganic Chemistry Communications*, 5(9), 719–723.
- Nizam Mohideen, M., Thenmozhi, S., Subbiah Pandi, A., Murugan, R., & Narayanan, S. S. (2007). (1 E , 4 E)-1,5-Bis(2-chlorophenyl)penta-1,4-dien-3-one. *Acta Crystallographica Section E Structure Reports Online*, 63(11), o4379–o4379.
- Ogasawara, M., Ikeda, H., Nagano, T., & Hayashi, T. (2001). Palladium-catalyzed asymmetric synthesis of axially chiral allenes: A synergistic effect of dibenzalacetone on high enantioselectivity. *Journal of the American Chemical Society*, 123(9), 2089-2090.
- Oliver, J. W. (1975). Interrelationships between athyrotic and copper-deficient states in rats. *American Journal of Veterinary Research*, 37(5), 597-600.
- Oosterlinck, W., Lobel, B., Jakse, G., Malmström, P. U., Stöckle, M., & Sternberg, C. (2002). Guidelines on bladder cancer. *European Urology*, 41(2), 105-112.
- Otwinowski, Z., Minor, W., & Mode, O. (1997). Processing of X-Ray Diffraction Data Collected in Oscillation Mode BT - Methods in Enzymology. *Methods in Enzymology*, 307-326.

- Pandey, K. B., & Rizvi, S. I. (2009). Plant polyphenols as dietary antioxidants in human health and disease. *Oxidative Medicine and Cellular Longevity*, 270-278.
- Pasikanti, K. K., Esuvaranathan, K., Ho, P. C., Mahendran, R., Kamaraj, R., Wu, Q. H., ... Chan, E. C. Y. (2010). Noninvasive urinary metabonomic diagnosis of human bladder cancer. *Journal of Proteome Research*. Pelosi, G. (2010). Thiosemicarbazone Metal Complexes: From Structure to Activity. *The Open Crystallography Journal*, 3(2), 16–28.
- Perrin, C. L., & Chang, K. L. (2016). The Complete Mechanism of an Aldol Condensation. *Journal of Organic Chemistry*, 81(13), 5631–5635.
- Prasad, A. S. (2012). Discovery of human zinc deficiency: 50 years later. IX ISTERH Conference. Trace Elements in Health and Disease: Essentiality, Toxicity. *Journal of Trace Elements in Medicine and Biology*, 66-69.
- Perrin, C. L., & Chang, K.-L. (2016). The Complete Mechanism of an Aldol Condensation. *The Journal of Organic Chemistry*, 81(13), 5631–5635. <https://doi.org/10.1021/acs.joc.6b00959>
- Rajasekar, M., Muthu, K., Bhagavannarayana, G., & Meenakshisundaram, S. P. (2012). Synthesis, structure, growth and characterization of an organic crystal: 1,5-diphenylpenta-2,4-dien-1-one. *Journal of Applied Crystallography*, 45(5), 914-920.
- Raman, N., Johnson Raja, S., Joseph, J., Sakthivel, A., & Dhaweethu Raja, J. (2008). Designing, synthesis, spectral characterization of antimicrobial and DNA active tridentate Schiff base ligands and their complexes. *Journal of the Chilean Chemical Society*, 53(3), 1599–1604.
- Rao, M. J., & Anderson, R. S. (1965). Electron Spin Resonance in Gamma-Irradiated Single Crystals of Hydroxylated Organic Compounds. *The Journal of Chemical Physics*, 42(8), 2899–2904.
- Ravoof, T. B. S. A., Crouse, K. A., Tahir, M. I. M., How, F. N. F., Rosli, R., & Watkins, D. J. (2010). Synthesis, characterization and biological activities of 3-methylbenzyl 2-(6-methyl pyridin-2-ylmethylene)hydrazine carbodithioate and its transition metal complexes. *Transition Metal Chemistry*, 35(7), 871–876.
- Ravoof, T. B. S. A., Crouse, K. A., Tahir, M. I. M., Rosli, R., Watkin, D. J., & How, F. N. F. (2011). Synthesis, characterisation and biological activities of 2-methylbenzyl 2-(dipyridin-2-yl methylene) hydrazinecarbodithioate. *Journal of Chemical Crystallography*, 41(4), 491–495.
- Ronconi, L., Marzano, C., Zanello, P., Corsini, M., Miolo, G., Maccà, C., Fregona, D. (2006). Gold(III) dithiocarbamate derivatives for the treatment of cancer: Solution chemistry, DNA binding, and hemolytic properties. *Journal of Medicinal Chemistry*, 49(5), 1648–1657.

- Ronconi, L., & Sadler, P. J. (2007). Using coordination chemistry to design new medicines. *Coordination Chemistry Reviews*, 251, 1633-1648.
- Rossi, L., Lippe, G., Marchese, E., De Martino, A., Mavelli, I., Rotilio, G., & Ciriolo, M. R. (1998). Decrease of cytochrome c oxidase protein in heart mitochondria of copper-deficient rats. *BioMetals*, 11(3), 207-212.
- Sánchez-Delgado, R. A., Navarro, M., Pérez, H., & Urbina, J. A. (1996). Toward a Novel Metal-Based Chemotherapy against Tropical Diseases. 2. Synthesis and Antimalarial Activity in Vitro and in Vivo of New Ruthenium- and Rhodium-Chloroquine Complexes. *Journal of Medicinal Chemistry*, 39(5), 1095-1099.
- Sankaraperumal, A., Karthikeyan, J., Shetty, A. N., & Lakshmisundaram, R. (2013). Nickel(II) complex of p-[N,N-bis(2-chloroethyl)amino]benzaldehyde-4-methyl thiosemicarbazone: Synthesis, structural characterization and biological application. *Polyhedron*, 50(1), 264-269.
- Saxena, A., & Tandon, J. P. (1983). Antitumor activity of some diorganotin and tin(IV) complexes of Schiff bases. *Cancer Letters*, 19(1), 73-76.
- Sengupta, S. K., Pandey, O. P., Rao, G. P., Dwivedi, A., & Singh, P. (2003). Efficacy of Organophosphorus Derivatives Containing Substituted Chalcone Thiosemicarbazones and Dithiocarbazates Against Fungal Pathogens of Sugarcane. *Phosphorus, Sulfur, and Silicon and the Related Elements*, 178(4), 839-849.
- Soliman, A. A., & Linert, W. (2007). Structural features of ONS-donor salicylidene Schiff base complexes. *Monatshefte Fur Chemie*.138(3), 175-189.
- Stringer, T., Therrien, B., Hendricks, D. T., Guzgay, H., & Smith, G. S. (2011). Mono- and dinuclear (η^6 -arene) ruthenium(II) benzaldehyde thiosemicarbazone complexes: Synthesis, characterization and cytotoxicity. *Inorganic Chemistry Communications*, 14(6), 956-960.
- Swarts, J. C., Cook, M. J., & Baker, E. N. (2008). Metal-containing proteins, macrocycles, and coordination complexes in therapeutic applications and disease. *Metal-Based Drugs*, 2008, 1-2.
- Tabatabaee, M., Sharif, M. A., Khalili, R., & Parvez, M. (2010). Ethoxycarbonylmethyl 3-(4-chlorobenzylidene)dithiocarbazate. *Acta Crystallographica Section E: Structure Reports Online*, 66(10), o2545-o2545.
- Takjoo, R., Centore, R., Hakimi, M., Ali Beyramabadi, S., & Morsali, A. (2011). S-allyl-3-(2-pyridyl-methylene)dithiocarbazate ligand and its manganese(II), cobalt(III) and nickel(II) complexes. *Inorganica Chimica Acta*, 371(1), 36-41.
- Tampouris, K., Coco, S., Yannopoulos, A., & Koinis, S. (2007). Palladium(II) complexes with S-benzyl dithiocarbazate and S-benzyl-N-isopropylidenedithiocarbazate: Synthesis, spectroscopic properties and X-ray

crystal structures. *Polyhedron*, 26(15), 4269–4275.

- Tarafder, M. T. ., Khoo, T.-J., Crouse, K. A., Ali, A. ., Yamin, B. ., & Fun, H.-K. (2002a). Coordination chemistry and bioactivity of some metal complexes containing two isomeric bidentate NS Schiff bases derived from S-benzylthiocarbamate and the X-ray crystal structures of S-benzyl- β -N-(5-methyl-2-furylmethylene)dithiocarbamate and bis[S-ben. *Polyhedron*, 21(27–28), 2691–2698.
- Tarafder, M. T. H., Asmadi, A., Talib, S. M. S., Ali, A. M., & Crouse, K. A. (2001). Studies on coordination chemistry of a nitrogen-sulfur donor ligand with lighter and heavier metal ions and biological activities of its complexes. *Transition Metal Chemistry*, 26(1–2), 170–174.
- Tarafder, M. T. H., Jalil Miah, M. A., Bose, R. N., & Akbar Ali, M. (1981). Metal complexes of some schiff bases derived from s-benzylthiocarbamate. *Journal of Inorganic and Nuclear Chemistry*, 43(12), 3151-3157.
- Tarafder, M. T. H., Jin, K. T., Crouse, K. A., Ali, A. M., Yamin, B. M., & Fun, H.-K. (2002b). Coordination chemistry and bioactivity of Ni²⁺, Cu²⁺, Cd²⁺ and Zn²⁺ complexes containing bidentate Schiff bases derived from S-benzylthiocarbamate and the X-ray crystal structure of bis [S-benzyl-b-N-(5-methyl-2-furylmethylene) dithiocarbamate]cadm. *Polyhedron*, 21(25–26), 2547–2554.
- Tarafder, M. T. H., Khan, S. S., Islam, M. a. a. a., Lorenzi, L., & Zangrando, E. (2010). Methyl 3-[(E , E)-3-phenylprop-2-enylidene]dithiocarbamate. *Acta Crystallographica Section E Structure Reports Online*, 66(11), o2851–o2851.
- Tarafder, M. T. H., Manaf Ali, A., Elias, M. S., Grouse, K. A., & Silong, S. (2000). Coordination chemistry and biological activity of bidentate nitrogen-sulfur donor ligands & their complexes. *Transition Metal Chemistry*, 25(6), 706–710.
- Testelin, C., Rigaux, C., Mauger, A., Mycielski, A., & Julien, C. (1992). Dynamic Jahn-Teller effect on the far-infrared spectrum of Fe²⁺ in Cd_{1-x}Fe_xTe compounds. *Physical Review B*. Thomas, G. (2007). Structure-Activity and Quantitative Structure Relationships. In *Medicinal Chemistry an Introduction - 2nd Edition*, pp. 637-641.
- Thompson, K. H., & Orvig, C. (2006). Metal complexes in medicinal chemistry: new vistas and challenges in drug design. *Dalton Transactions (Cambridge, England : 2003)*, (6), 761–764.
- Tiwari, A. K., & Roy, H. K. (2012). Progress against cancer (1971-2011): How far have we come? *Journal of Internal Medicine*, 271(4), 392-399.
- Tofazzal, M., Tarafder, H., Ali, M. A., Saravanan, N., Weng, W. Y., Kumar, S., & Crouse, K. A. (2000). Coordination chemistry and biological activity of two tridentate ONS and NNS Schiff bases derived from S-benzylthiocarbamate. *Transition Metal Chemistry*, 25(3), 295–298.

- Tofazzal, M., Asmadi, A., Siti M. S. Talib, Ali, M. A. & Crouse, K. A. (2001). Studies on coordination chemistry of a nitrogen–sulfur donor ligand with lighter and heavier metal ions and biological activities of its complexes. *Transition Metal Chemistry*, 26(1), 170-174.
- van Rijt, S. H., & Sadler, P. J. (2009, December). Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. *Drug Discovery Today*, 14(23-24), 1089-1097.
- Wang, X. Y., Jin, B. K., Tian, Y. P., & Lin, X. Q. (2003). [Study on S-benzyl-N-(ferrocenyl-1-methyl-methylidene)-dithiocarbazate nickel (II)/cobalt (II) complexes by in-situ FTIR spectroelectrochemistry]. *Guang Pu Xue Yu Guang Pu Fen Xi*, 23(1), 42-45.
- Young, H., Sadler, K., & Borrel, A. (2012). Public Nutrition in Humanitarian Crises. In *Present Knowledge in Nutrition: Tenth Edition*, pp.1182-1205.
- Young, Z. D., Hanspal, S., & Davis, R. J. (2016). Aldol Condensation of Acetaldehyde over Titania, Hydroxyapatite, and Magnesia. *ACS Catalysis*, 6(5), 3193–3202. <https://doi.org/10.1021/acscatal.6b00264>
- Yueh, T. M. (2015). *Synthesis and cytotoxicity of dithiocarbazate and thiosemicarbazide Schiff bases derived from chalcone and phenylbutanone analogues and their Cd(II) and Zn(II) complexes*. Universiti Putra Malaysia.
- Yusof, E. N. M., Ravoof, T. B. S. A., Jamsari, J., Tiekink, E. R. T., Veerakumarasivam, A., Crouse, K. A., & Ahmad, H. (2015). Synthesis, characterization and biological studies of S-4-methylbenzyl-β-N-(2-furylmethylene)dithiocarbazate (S4MFuH) its Zn²⁺, Cu²⁺, Cd²⁺ and Ni²⁺ complexes. *Inorganica Chimica Acta*, 438, 85–93.
- Zaheer-ul-Haq, Lodhi, M. A., Ahmad Nawaz, S., Iqbal, S., Mohammed Khan, K., Rode, B. M., & Choudhary. (2008). 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: A strategic design in anti-urease agents. *Bioorganic and Medicinal Chemistry*, 16(6), 3456-3461.
- Zangrando, E., Begum, M. S., Sheikh, M. C., Miyatake, R., Hossain, M. M., Alam, M. M., & Ghosh, A. (2017). Synthesis, characterization, density functional study & antimicrobial evaluation of a series of bischelated complexes with a dithiocarbazate Schiff base ligand. *Arabian J. of Chemistry*, 10(2), 172–184.
- Zhang, H., Chun-Sen, L. & Xian-HeBu, M. Y. (2012). Synthesis, crystal structure, cytotoxic activity and DNA-binding properties of the copper(II) and zinc(II) complexes with 1-[3-(2-pyridyl)pyrazol-1-ylmethyl]naphthalene. *Journal of Inorganic Biochemistry*, 99(5), 1119-1125.